DICE Therapeutics, Inc.
DICEDelisted Aug 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645569
DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.
Q4 2021 vs. Q3 2021
How the institutions holding DICE Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 39 | 1 | 69 | +31 |
| Shares | 24.4M | 43.1K | 31.7M | +7.35M (+30.2%) |
| Value | $793.6M | $1.41M | $799.4M | +$7.12M (+0.9%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (40)
Institutions that held DICE Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (9)
Institutions that held DICE Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| OrbiMed Advisors LLC | 440,000 | $14.4M |
| Sphera Funds Management Ltd. | 85,000 | $2.78M |
| Ergoteles LLC | 40,800 | $1.34M |
| Goldman Sachs Group Inc | 39,000 | $1.28M |
| Atika Capital Management LLC | 28,389 | $930.0K |
| Maven Securities LTD | 8,065 | $264.0K |
| Samson Rock Capital LLP | 7,333 | $240.0K |
| Qube Research & Technologies Ltd | 6,788 | $222.0K |
| Point72 Hong Kong Ltd | 6,205 | $203.0K |
Not filed for Q4 2021 yet (1)
Institutions that held DICE Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 43,062 | $1.41M |